Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alignment Healthcare (ALHC) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Alignment Healthcare (ALHC) over the last 4 years, with Q3 2025 value amounting to $5.5 million.

  • Alignment Healthcare's Capital Expenditures fell 4076.51% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year decrease of 2736.89%. This contributed to the annual value of $41.4 million for FY2024, which is 1506.6% up from last year.
  • Per Alignment Healthcare's latest filing, its Capital Expenditures stood at $5.5 million for Q3 2025, which was down 4076.51% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Alignment Healthcare's Capital Expenditures registered a high of $21.4 million during Q4 2022, and its lowest value of $1.1 million during Q1 2022.
  • In the last 4 years, Alignment Healthcare's Capital Expenditures had a median value of $8.9 million in 2023 and averaged $8.8 million.
  • The largest annual percentage gain for Alignment Healthcare's Capital Expenditures in the last 5 years was 64632.81% (2023), contrasted with its biggest fall of 5043.73% (2023).
  • Over the past 4 years, Alignment Healthcare's Capital Expenditures (Quarter) stood at $21.4 million in 2022, then plummeted by 50.44% to $10.6 million in 2023, then decreased by 12.39% to $9.3 million in 2024, then plummeted by 40.79% to $5.5 million in 2025.
  • Its Capital Expenditures was $5.5 million in Q3 2025, compared to $8.0 million in Q2 2025 and $8.3 million in Q1 2025.